Study of XL647 Administered Orally Daily to Patients With Solid Tumors

NCT00336765 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
31
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Kadmon Corporation, LLC